-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on September 1 A few days ago, Jiangsu Hengrui Pharmaceutical entered the administrative examination and approval stage with generic 4 types of febuxostat tablets and is expected to be approved
.
Prior to this, Jiangsu Hengrui Medicine has been approved in two specifications of 40mg and 80mg
.
According to Mi Nei.
com, in 2020, the total sales of febuxostat tablets in the terminals of public medical institutions in China and physical pharmacies in cities in China will reach nearly 2 billion yuan
.
.
Prior to this, Jiangsu Hengrui Medicine has been approved in two specifications of 40mg and 80mg
.
According to Mi Nei.
com, in 2020, the total sales of febuxostat tablets in the terminals of public medical institutions in China and physical pharmacies in cities in China will reach nearly 2 billion yuan
.
Data show that febuxostat is suitable for long-term treatment of hyperuricemia with gout symptoms and is not recommended for hyperuricemia without clinical symptoms
.
Febuxostat is a xanthine oxidase (XO) inhibitor, which reduces serum uric acid concentration by inhibiting uric acid synthesis, thereby achieving clinical therapeutic effects
.
.
Febuxostat is a xanthine oxidase (XO) inhibitor, which reduces serum uric acid concentration by inhibiting uric acid synthesis, thereby achieving clinical therapeutic effects
.
In recent years, the sales of febuxostat tablets in physical pharmacies in cities in China (unit: 100 million yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Febuxostat tablets are the largest variety of anti-gout preparations
.
According to Meinenet data, in 2020, the total sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacies will exceed 2 billion.
Among them, the growth rate of physical pharmacies in cities in China is the fastest, exceeding 25%
.
.
According to Meinenet data, in 2020, the total sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacies will exceed 2 billion.
Among them, the growth rate of physical pharmacies in cities in China is the fastest, exceeding 25%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, there are 7 manufacturers of febuxostat tablets, of which 6 domestic companies , including Jiangsu Wanbang Biochemical and Pharmaceutical Group, Jiangsu Hengrui Pharmaceutical, and Guangdong Dongyang Sunshine Pharmaceutical, have all been reviewed .
More than 10 companies including Chengdu Better Pharmaceutical, Yangzijiang Pharmaceutical Group, Qingdao Baiyang Pharmaceutical, etc.
have submitted their listing applications for review and approval .
More than 10 companies including Chengdu Better Pharmaceutical, Yangzijiang Pharmaceutical Group, Qingdao Baiyang Pharmaceutical, etc.
have submitted their listing applications for review and approval .
It is worth mentioning that febuxostat tablets are the third batch of centralized procurement.
Jiangsu Wanbang Biochemical, Jiangsu Hengrui Pharmaceutical, and Hangzhou Zhuyangxin Pharmaceutical won the bid.
The third batch of centralized procurement will be implemented at the end of 2020.
The market competition for this product will become more intense
.
Jiangsu Wanbang Biochemical, Jiangsu Hengrui Pharmaceutical, and Hangzhou Zhuyangxin Pharmaceutical won the bid.
The third batch of centralized procurement will be implemented at the end of 2020.
The market competition for this product will become more intense
.
Data source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Medical Network News on September 1 A few days ago, Jiangsu Hengrui Pharmaceutical entered the administrative examination and approval stage with generic 4 types of febuxostat tablets and is expected to be approved
.
Prior to this, Jiangsu Hengrui Medicine has been approved in two specifications of 40mg and 80mg
.
According to Mi Nei.
com, in 2020, the total sales of febuxostat tablets in the terminals of public medical institutions in China and physical pharmacies in cities in China will reach nearly 2 billion yuan
.
.
Prior to this, Jiangsu Hengrui Medicine has been approved in two specifications of 40mg and 80mg
.
According to Mi Nei.
com, in 2020, the total sales of febuxostat tablets in the terminals of public medical institutions in China and physical pharmacies in cities in China will reach nearly 2 billion yuan
.
Data show that febuxostat is suitable for long-term treatment of hyperuricemia with gout symptoms and is not recommended for hyperuricemia without clinical symptoms
.
Febuxostat is a xanthine oxidase (XO) inhibitor, which reduces serum uric acid concentration by inhibiting uric acid synthesis, thereby achieving clinical therapeutic effects
.
.
Febuxostat is a xanthine oxidase (XO) inhibitor, which reduces serum uric acid concentration by inhibiting uric acid synthesis, thereby achieving clinical therapeutic effects
.
In recent years, the sales of febuxostat tablets in physical pharmacies in cities in China (unit: 100 million yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Febuxostat tablets are the largest variety of anti-gout preparations
.
According to Meinenet data, in 2020, the total sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacies will exceed 2 billion.
Among them, the growth rate of physical pharmacies in cities in China is the fastest, exceeding 25%
.
.
According to Meinenet data, in 2020, the total sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacies will exceed 2 billion.
Among them, the growth rate of physical pharmacies in cities in China is the fastest, exceeding 25%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, there are 7 manufacturers of febuxostat tablets, of which 6 domestic companies , including Jiangsu Wanbang Biochemical and Pharmaceutical Group, Jiangsu Hengrui Pharmaceutical, and Guangdong Dongyang Sunshine Pharmaceutical, have all been reviewed .
More than 10 companies including Chengdu Better Pharmaceutical, Yangzijiang Pharmaceutical Group, Qingdao Baiyang Pharmaceutical, etc.
have submitted their listing applications for review and approval .
More than 10 companies including Chengdu Better Pharmaceutical, Yangzijiang Pharmaceutical Group, Qingdao Baiyang Pharmaceutical, etc.
have submitted their listing applications for review and approval .
It is worth mentioning that febuxostat tablets are the third batch of centralized procurement.
Jiangsu Wanbang Biochemical, Jiangsu Hengrui Pharmaceutical, and Hangzhou Zhuyangxin Pharmaceutical won the bid.
The third batch of centralized procurement will be implemented at the end of 2020.
The market competition for this product will become more intense
.
Jiangsu Wanbang Biochemical, Jiangsu Hengrui Pharmaceutical, and Hangzhou Zhuyangxin Pharmaceutical won the bid.
The third batch of centralized procurement will be implemented at the end of 2020.
The market competition for this product will become more intense
.
Data source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Medical Network News on September 1 A few days ago, Jiangsu Hengrui Pharmaceutical entered the administrative examination and approval stage with generic 4 types of febuxostat tablets and is expected to be approved
.
Prior to this, Jiangsu Hengrui Medicine has been approved in two specifications of 40mg and 80mg
.
According to Mi Nei.
com, in 2020, the total sales of febuxostat tablets in the terminals of public medical institutions in China and physical pharmacies in cities in China will reach nearly 2 billion yuan
.
.
Prior to this, Jiangsu Hengrui Medicine has been approved in two specifications of 40mg and 80mg
.
According to Mi Nei.
com, in 2020, the total sales of febuxostat tablets in the terminals of public medical institutions in China and physical pharmacies in cities in China will reach nearly 2 billion yuan
.
Data show that febuxostat is suitable for long-term treatment of hyperuricemia with gout symptoms and is not recommended for hyperuricemia without clinical symptoms
.
Febuxostat is a xanthine oxidase (XO) inhibitor, which reduces serum uric acid concentration by inhibiting uric acid synthesis, thereby achieving clinical therapeutic effects
.
.
Febuxostat is a xanthine oxidase (XO) inhibitor, which reduces serum uric acid concentration by inhibiting uric acid synthesis, thereby achieving clinical therapeutic effects
.
In recent years, the sales of febuxostat tablets in physical pharmacies in cities in China (unit: 100 million yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Febuxostat tablets are the largest variety of anti-gout preparations
.
According to Meinenet data, in 2020, the total sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacies will exceed 2 billion.
Among them, the growth rate of physical pharmacies in cities in China is the fastest, exceeding 25%
.
Hospital hospital hospital pharmacy pharmacy pharmacy.
According to Meinenet data, in 2020, the total sales of febuxostat tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacies will exceed 2 billion.
Among them, the growth rate of physical pharmacies in cities in China is the fastest, exceeding 25%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, there are 7 manufacturers of febuxostat tablets, of which 6 domestic companies , including Jiangsu Wanbang Biochemical and Pharmaceutical Group, Jiangsu Hengrui Pharmaceutical, and Guangdong Dongyang Sunshine Pharmaceutical, have all been reviewed .
More than 10 companies including Chengdu Better Pharmaceutical, Yangzijiang Pharmaceutical Group, Qingdao Baiyang Pharmaceutical, etc.
have submitted their listing applications for review and approval .
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise EnterpriseMore than 10 companies including Chengdu Better Pharmaceutical, Yangzijiang Pharmaceutical Group, Qingdao Baiyang Pharmaceutical, etc.
have submitted their listing applications for review and approval .
It is worth mentioning that febuxostat tablets are the third batch of centralized procurement.
Jiangsu Wanbang Biochemical, Jiangsu Hengrui Pharmaceutical, and Hangzhou Zhuyangxin Pharmaceutical won the bid.
The third batch of centralized procurement will be implemented at the end of 2020.
The market competition for this product will become more intense
.
Jiangsu Wanbang Biochemical, Jiangsu Hengrui Pharmaceutical, and Hangzhou Zhuyangxin Pharmaceutical won the bid.
The third batch of centralized procurement will be implemented at the end of 2020.
The market competition for this product will become more intense
.
Data source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
